A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor, Adult|Advanced Solid Tumor|Head and Neck Cancer|Breast Cancer|Colon Cancer|Pancreatic Cancer|Gastric Cancer|Esophageal Cancer|Prostate Cancer|Uterine Cancer|Cervix Cancer|Ovarian Cancer|Kidney Cancer|Bladder Cancer|Thyroid Cancer|Melanoma|Sarcoma|Advanced Cancer|Metastatic Cancer|Refractory Cancer|Non Small Cell Lung Cancer
Interventions: DRUG: SNS-101 (anti-VISTA)|DRUG: Cemiplimab
Sponsor: Sensei Biotherapeutics, Inc.
Collaborators: Regeneron Pharmaceuticals